Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

CONCLUSIONS: The cumulative incidence of thrombosis during ibrutinib treatment was low (1.7 per 100 person-years), with the majority being arterial. Prior thrombosis was associated with increased venous thrombosis risk. There are more bleeding than thrombotic complications after patients develop thromboses on ibrutinib, and optimal treatment strategies for this population requires further investigation.DisclosuresKander: AstraZeneca: Consultancy. Wang: Daiichi Sankyo: Consultancy, Other: Travel.

Source: Blood - November 21, 2018 Category: Hematology Authors: Kander, E., Zhao, Q., Wiczer, T., Byrd, J. C., Woyach, J. A., Awan, F. T., Rogers, K. A., Wang, T.-F. Tags: 642. CLL: Therapy, excluding Transplantation: Poster II Source Type: research